James E. Levine's most recent trade in Cardiff Oncology Inc was a trade of 332,621 Stock Options done . Disclosure was reported to the exchange on March 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2025 | 332,621 | 1,295,117 | - | - | Stock Options | |
| Cardiff Oncology Inc | Levine James E. | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 16 Dec 2024 | 2,752 | 65,316 (0%) | 0% | 5.4 | 14,905 | Common Stock |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.83 per share. | 16 Dec 2024 | 2,564 | 62,564 (0%) | 0% | 3.8 | 9,820 | Common Stock |
| Cardiff Oncology Inc | James Levine E. | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 16 Dec 2024 | 2,400 | 67,716 (0%) | 0% | 5 | 12,000 | Common Stock |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 205,008 | 962,496 | - | - | Stock Options | |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 197,472 | 757,488 | - | - | Stock Options | |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.56 per share. | 16 Sep 2022 | 30,000 | 60,000 (0%) | 0% | 1.6 | 46,710 | Common Stock |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 170,016 | 560,016 | - | - | Stock Options | |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.38 per share. | 10 Sep 2021 | 10,000 | 20,000 (0%) | 0% | 6.4 | 63,800 | Common Stock |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.62 per share. | 10 Sep 2021 | 5,000 | 5,000 (0%) | 0% | 6.6 | 33,100 | Common Stock |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.32 per share. | 10 Sep 2021 | 5,000 | 30,000 (0%) | 0% | 6.3 | 31,600 | Common Stock |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.35 per share. | 10 Sep 2021 | 5,000 | 25,000 (0%) | 0% | 6.4 | 31,750 | Common Stock |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 6.75 per share. | 10 Sep 2021 | 5,000 | 10,000 (0%) | 0% | 6.8 | 33,750 | Common Stock |
| Cardiff Oncology Inc | James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jul 2021 | 390,000 | 390,000 | - | - | Common Stock | |
| Cidara Therapeutics Inc | James E. Levine | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2021 | 130,000 | 130,000 | - | - | Employee Stock Option (right to buy) | |
| Cidara Therapeutics Inc | James E. Levine | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.01 per share. | 10 Nov 2020 | 50,000 | 50,000 (0%) | 0% | 2.0 | 100,720 | Common Stock |